

Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

Abiraterone

Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

Adalimumab

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL;

10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Axial spondyloarthritis

Crohn disease site

Rheumatoid arthritis

Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section

Targeted therapies

Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section

Supportive medicines

Oral > Solid: 100 mg; 300 mg

Indications

Tumour lysis syndrome

Anastrozole

Section

Hormones and antihormones

Oral > Solid: 1 mg tablet

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Arsenic trioxide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section

Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Atezolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Axicabtagene ciloleucel

Section

Antineoplastics and supportive medicines

Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

Azacitidine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

Azathioprine

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 25 mg; 50 mg (scored)

Oral > Solid > tablet: 50 mg (scored)

Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Bendamustine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Bicalutamide

Section

Hormones and antihormones

Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Bleomycin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

Bortezomib

Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capecitabine

Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Carboplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Cemiplimab

Section

Immunomodulators

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Chlorambucil

Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ciclosporin

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

Cisplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Cladribine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Langerhans cell histiocytosis

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Cyclophosphamide

Section

Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Malignant neoplasms of breast

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Plasma cell myeloma

Other specified gliomas of brain

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Cytarabine

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Dabrafenib

Section

Targeted therapies

Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Daratumumab

Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Dexamethasone

Section

Hormones and antihormones

Oral > Solid: 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Indications

Plasma cell myeloma

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Docetaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Plasma cell myeloma

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Durvalumab

Section

Immunomodulators

Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial

Indications

Other specified malignant neoplasms of bronchus or lung

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Enzalutamide

Section

Hormones and antihormones

Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Etoposide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Everolimus

Section

Targeted therapies

Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg

Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

Other specified gliomas of brain

Filgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

Fingolimod

Section

Immunomodulators for non-malignant disease
Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Fludarabine

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section

Cytotoxic medicines
Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per mL in vial

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Fulvestrant

Section

Hormones and antihormones
Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of prostate

Hydrocortisone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Hydroxycarbamide (hydroxyurea)

Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to **adalimumab** for

Axial spondyloarthritis

Therapeutic equivalent to **adalimumab** for

Crohn disease site

Therapeutic equivalent to **adalimumab** for

Rheumatoid arthritis

Irinotecan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Lenalidomide

Section

Immunomodulators

Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Leuprorelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to **axicabtagene ciloleucel** for

Diffuse large B-cell lymphomas

Melphalan

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Mesna

Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Methotrexate

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Immunomodulators for non-malignant disease

Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Malignant trophoblastic neoplasms of placenta

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Crohn disease site

Psoriatic arthritis

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Nilotinib

Section

Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Paclitaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section

Immunomodulators

Parenteral > General injections > IV: 50 mg powder for injection

Indications

Therapeutic equivalent to nivolumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Pertuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of prostate

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphomas

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Rasburicase

Section

Supportive medicines

Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution

Indications

Tumour lysis syndrome

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Tacrolimus

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Thalidomide

Section

Immunomodulators
Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tioguanine

Section

Cytotoxic medicines
Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

Tislelizumab

Section

Immunomodulators
Parenteral > General injections > IV: 100 mg per 10 mL

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Toripalimab

Section

Immunomodulators
Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus

Trametinib

Section

Targeted therapies
Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Trastuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin for

Malignant neoplasms of prostate

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

Vinblastine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis

Vincristine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Retinoblastoma

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Vinorelbine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

Other specified malignant neoplasms of breast

Other specified malignant neoplasms of bronchus or lung

Rhabdomyosarcoma primary site

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zoledronic acid

Section

Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow